On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Genomics (NASDAQ:TXG – Get Free Report) is projected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect 10x Genomics to post earnings of ($0.29) per ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

10x Genomics disclaims any intention or obligation ... I'll start with the product innovations we introduced in 2024. First on our Chromium platform. Last year was the biggest year of Chromium ...

Genomics, Inc. , a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for ...

chromium controllers, informatics software, and 10x-compatible products. Cathie Wood recently made a significant investment in 10x Genomics Inc. (NASDAQ:TXG), with ARK purchasing 247,089 shares ...